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The precursor for transforming growth factor-a 
(TGF-a) is a membrane glycoprotein that can establish 
contact with epidermal growth factor/TGF-a receptors 
on adjacent cells or can be cleaved to release TGF-cy 
that diffuses into the medium. Cleavage of pro-TGF-cr 
occurs at Ala/Leu-Ala/Leu-Ala-Val-Val sites located at 
each end of the mature TGF-a sequence. To character- 
ize the cleavage process of pro-TGF-cY and the role of 
glycosylation in this process, we have introduced a pro- 
TGF-cr expression vector in wild type Chinese hamster 
ovary (CHO) cells and in the mutant CHO cell clone 
ZdZD that has a reversible defect in protein glycosyla- 
tion. Analysis of metabolically labeled and cell surface- 
labeled products immunoprecipitated with antibodies 
directed against the extracellular TGF-a sequence and 
the cytoplasmic pro-TGF-cr C-terminal domain shows 
that cleavage of pro-TGF-cu in wild type CHO cells 
occurs in two steps. Both processing steps occur after 
pro-TGF-a reaches the cell surface. In the first step, 
pro-TGF-cw rapidly (tH = 30 min) loses the amino-ter- 
minal segment that precedes the TGF-(U sequence. In 
the second step, pro-TGF-cr is cleaved at the carboxyl 
terminus of the TGF-cx sequence releasing this factor 
into the medium. This second step is slow (tU = 2 h). 
The action of pancreatic elastase added to CHO-TGF- 
(Y cells mimics the first step but not the second one. 
Synthesis, cell surface exposure, rate of cleavage, and 
generation of bioactive TGF-(U in ZdlD-TGF-cr cells are 
not markedly affected by the lack of N-acetylgalac- 
tosamine-dependent protein 0-glycosylation or galac- 
tose-dependent glycan chain modification. The results 
indicate that, despite their similarity in amino acid 
sequence, the two cleavage sites that flank TGF-cx may 
be processed with different kinetics which can lead to 
retention of pro-TGF-cw on the cell surface. 
Transforming growth factor-a (TGF-(u)’ is a mitogenic 
polypeptide first identified in the culture fluids of various 
tumor-derived, retrovirally transformed, and chemically 
transformed cells (l-3, for review, see Ref. 4) but expressed 
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also in normal skin, pituitary, and decidua cells (5-7). TGF- 
01 is structurally and functionally related to epidermal growth 
factor (EGF) (3, 7-10). These two factors are indistinguisha- 
ble in their ability to bind to and activate the same receptor 
in mammalian cells (11, 12) but differ in their ability to 
interact with the avian receptor which has higher affinity for 
TGF-a than for EGF (13). 
An important feature of TGF-cu and related factors is that 
they are synthesized as part of transmembrane glycoprotein 
precursors. In addition to EGF (14, 15) and TGF-(Y (9, lo), 
other members of this family include vaccinia growth factor 
that is encoded by vaccinia virus (16-M), the products of two 
Drosophila neurogenic genes, Notch and Delta (19, 20), and 
the products of two genes, lin-12 and &p-l, that determine 
cell fate in the nematode Cuenorhudditis eleguns (21-24). 
Colony-stimulating factor-l and tumor necrosis factor-a are 
not members of the EGF family, but are also synthesized as 
part of membrane-bound precursors (25, 26). 
The TGF-a! precursor, pro-TGF-a, is a polypeptide of 159 
(rat) or 160 (human) amino acids with a sequence of 23 
hydrophobic amino acids that starts at residue 97 or 98 (9, 
10) and acts as a membrane-spanning domain (27, 28). The 
50-amino acid TGF-a sequence is located in the extracellular 
domain or pro-TGF-cu, starting with residue 39 or 40. The 
proteolytic process that releases mature TGF-a from pro- 
TGF-a! is inefficient under basal conditions in most cell types 
examined including tumor-derived cells, retrovirally trans- 
formed cells, and cells transfected with a TGF-a gene (29- 
34). As a result, cells release partially processed forms of 
TGF-(U or retain pro-TGF-cu on their surface. 
Uncleaved pro-TGF-oc expressed on the surface of one cell 
can establish contact with the EGF/TGF-(Y receptor on the 
surface of an adjacent cell and activate the receptor-associated 
tyrosine kinase activity (33, 34) and calcium uptake (33). 
Furthermore, cell-cell interactions mediated by the EGF 
receptor/pro-TGF-a pair can support cell adhesion associated 
with a mitogenic response.2 This form of cell-cell stimulation 
might play an important role in developmental processes that 
depend on discreet cell-cell interactions, or targeting pro- 
TGF-a expressing cells to tissue sites rich in TGF-a receptor. 
The events that convert pro-TGF-a from a membrane 
molecule to a diffusible autocrine/paracrine factor are poorly 
understood. These events could be the object of regulatory 
stimuli or the subject of defects that might lead to changes in 
the pattern of expression of the membrane-bound and secre- 
tory forms of TGF-o(. Preliminary studies on the biosynthesis 
of pro-TGF-o! have been reported (27, 29, 33, 34). However, 
the cellular location where pro-TGF-cy is cleaved, the mecha- 
nism that allows pro-TGF-cY to reach the cell surface un- 
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cleaved, and the role of post-translational modifications such 
as glycosylation in this process have been unknown. The 
present studies address some of these issues using as a model 
system CHO cells transfected with a pro-TGF-cy gene. The 
results show that processing of pro-TGF-a occurs mainly after 
this molecule reaches the cell surface.The different kinetics 
of cleavage at the TGF-LU flanking sites in the precursor 
provide an explanation for the accumulation of uncleaved 
pro-TGF-ol on the surface of CHO cells. 
EXPERIMENTAL PROCEDURES 
Cell Culture and Transfection-Parental CHO (clone Kl) (Ameri- 
can Type Culture Collection) and Z&D cells (obtained from M. Krie- 
ger, MIT, Ref. 35) were grown in MEM-ol medium supplemented with 
10% fetal bovine serum, penicillin (100 units/ml), and streptomycin 
(100 pg/ml) (complete medium). The pSV2-TGF-a vector was con- 
structed by placing the SmaI fragment of plasmid 3Blb (lo), which 
encodes the entire rat pro-TGF-a, under the control of a SV40 early 
promoter in an expression vector that also contains the mouse dihy- 
drofolate reductase gene under the control of a separate SV40 pro- 
moter (36). Subconfluent cells in loo-mm dishes grown in complete 
medium were co-transfected with 5 pg of pSV2-TGF-a DNA and 0.5 
UP of oZIP/neo DNA. which contains the bacterial transposon Tn5 , - 
neomycin resistance gene (37), as a calcium phosphate precipitate 
(38). Cells were incubated for 4 h at 37 “C with the plasmid DNA, 
and the medium was then removed. Cell cultures were incubated for 
3 min with 2.5 ml of 15% (v/v) glycerol. Cells were left in regular 
medium for 24 h and then selected in the same medium in the presence 
of 1 mg/ml G418 (Geneticin; Gibco Laboratories) until antibiotic- 
resistant colonies appeared. Antibiotic-resistant colonies were ring- 
cloned and analyzed for TGF-o( mRNA expression using a previously 
described RNase protection assay (39). Positive clones were cultured 
in the presence of stepwise increasing concentrations (up to 5 FM) of 
methotrexate to amplify TGF-cu expression. The cell clones with the 
highest level of TGF-a expression as determined by biosynthetic 
labeling and immunoprecipitation (see below) were used in all the 
experiments described in this study. These clones were designated 
CHO-TGF-cr (cl 10.7) (derived from parental CHO cells) and IdlD- 
TGF-cu (cl 014) (derived from CHO l&D cells), and were maintained 
in MEM-a medium lacking nucleotides and supplemented with 10% 
dialyzed fetal bovine serum. 
. _ 
Cell Labeling-For metabolic labeling of CHO-TGF-(Y cells, sub- 
confluent cultures in 60-mm dishes were placed in serum-free and 
cysteine-free MEM containing 150 &i per ml of [35S]cysteine (Du 
Pont-New England Nuclear). After 15 min, the radioactive medium 
was substituted with complete MEM. For metabolic labeling of I&D- 
TGF-(U cells, sparse cultures grown in MEM-a supplemented with 
10% dialyzed fetal calf serum were placed in MEM-ol supplemented 
with 1% ITS+ (a solution containing 0.63 mg/ml insulin, 0.63 mg/ml 
transferrin, 0.63 fig/ml selenous acid, 125 mg/ml bovine serum albu- 
min, and 0.53 mg/ml linoleic acid; Collaborative Research) with or 
without 10 pM galactose and/or 100 gM N-acetylgalactosamine. l&D- 
TGF-u cells were grown in this medium for 48 h and then metaboli- 
cally labeled as described above. The indicated sugar supplements 
were present in the labeling medium and in the chase medium. 
For incubations with elastase, metabolically labeled cell cultures 
were incubated for 15 min at 37 “C in MEM containing 300 pg/ml 
soybean trypsin inhibitor with or without 25 @g/ml porcine pancreatic 
elastase (Worthington). 
Cell surface iodination was performed with cells in suspension. 
Cells were detached by incubation for 10 min at 37 “C in 20 mM 
sodium phosphate-buffered isotonic saline solution, pH 7.4 (PBS 
buffer), containing 1 mM EDTA, and recovered by centrifugation at 
500 x g for 5 min. The samples were adjusted to contain equal 
numbers of cells in 1 ml of PBS buffer containina 0.2 mM ohenvl- 
methylsulfonyl fluoride. Iodination was carried &t on ice-by the 
addition of 0.5 mCi of Na’? (Amersham Corn.; 16 mCi/rre). 0.1 ma -. 
of lactoperoxidase, and 0.005% H,O,, with periodic mixing for 10 min. 
Cells were washed four times with PBS buffer containing 10 mM KI 
and 5 mM N-acetyltyrosine. These two components were also present 
in all buffers during immunoprecipitation of these samples. 
Zmmunoprecipitations-At the indicated times after metabolic 
labeling or cell surface labeling, cells were rinsed with immunoprecip- 
itation buffer (PBS buffer containing 1 mM EDTA, 0.5 mM phenyl- 
methylsulfonyl fluoride, 200 kallikrein inactivating units/ml of apro- 
tinin), scraped, and lysed in the same buffer containing 1% Nonidet 
P-40. Cell lysates were incubated with 5 mM dithiothreitol and 0.25% 
(w/v) sodium dodecyl sulfate for 20 min at 22 “C, followed by the 
addition of 10 mM N-ethylmaleimide prior to the addition of antibod- 
ies. This treatment increases the affinity of antigen for the anti-TGF- 
(Y antibodies. Anti-TGF-cu antibodies (raised against a synthetic pep- 
tide corresponding to residues 71-88 of the rat pro-TGF-n sequence 
or residues 33-50 of rat mature TGF-c() (30) or anti-pro-TGF-a 
antibodies (raised against a mixture of two synthetic peptides corre- 
sponding to residues 138-151 and 145-159 of rat pro-TGF-Lu) (28) 
were used in the immunoprecipitations at a 1:30 dilution. Immuno- 
complexes were harvested-with protein A-Sepharose and washed three 
times with PBS buffer containing 0.1% (v/v) Triton X-100, 0.02% 
sodium dodecyl sulfate, 0.5 mM phenylmethylsulfonyl fluoride, and 
200 kallikrein inactivating units/ml of aprotinin, and once with PBS 
alone. The Sepharose beads were boiled in electrophoresis sample 
buffer and electrophoresed on 12 to 18% polyacrylamide gradient gels 
containing sodium dodecyl sulfate. Gels were then stained with Coo- 
massie Blue and subjected to fluorography using Enlightning (Du 
Pont-New England Nuclear). 
For immunoprecipitation of labeled secretory products, the culture 
medium collected at the end of the labeling period received 0.1 mM 
phenylmethylsulfonyl fluoride and was dialyzed against 0.1 M acetic 
acid, lyophilized to dryness, resuspended in immunoprecipitation 
buffer, and subjected to the immunoprecipitation protocol described 
above. 
RESULTS 
Generation of CHO Cell Lines That Express TGF-a--To 
generate cell lines for the study of TGF-a biosynthesis, we 
transfected the pSV2-TGF-a plasmid that contains the rat 
pro-TGF-cu coding sequence transcribed under the control of 
an SV40 promoter (36). pSV2-TGF-u was transfected into 
wild type CHO cells and the mutant CHO cell clone, 1dZD 
(35). Transfected cells were selected for resistance to the 
antibiotic G418 conferred by the pZIP/neo vector (37) that 
had been co-transfected with pSV2-TGF-(Y into the cells. TO 
isolate cells with amplified pro-TGF-a expression, G418-re- 
sistant cell clones that had high levels of pro-TGF-a mRNA 
as determined by a RNase protection assay were selected for 
resistance to methotrexate conferred by overexpression of the 
dihydrofolate reductase gene present in the pSV2-TGF-cu 
vector (36). Cell clones CHO-TGF-(Y (cl 10.7) and IdGD-TGF- 
(Y (cl ot4) expressed the highest levels of pro-TGF-a and were 
used in this study. 
pro-TGF-a Processing in Parental CHO Cells-Immunopre- 
cipitation of lysates from CHO-TGF-a cells metabolically 
labeled for 15 min with [?S]cysteine yielded an 18-kDa la- 
beled product that was recognized by anti-pro-TGF-a anti- 
bodies directed against a cytoplasmic sequence of pro-TGF-ol 
(28) as well as by anti-TGF-a antibodies (30) directed against 
an extracellular TGF-(Y sequence (Fig. 1, A and B). Antibody 
recognition of this 18-kDa product and all other labeled 
species described in this study was specific as determined by 
competition with an excess of the corresponding immunogenic 
synthetic peptides during immunoprecipitation (data not 
shown; Refs. 28, 30, and 33). 
Within 15 min of metabolic chase with unlabeled medium, 
the 18-kDa pro-TGF-a form was almost completely converted 
into a 20-22-kDa product recognized by both antibodies (Fig. 
1, A and B). Generation of the 20-22-kDa pro-TGF-cY form 
was presumably due to the addition of carbohydrate during 
maturation of pro-TGF-oc through the Golgi (Refs. 27,29, and 
33 and see below). N- and 0-Glycosylation acceptor sites are 
located in the amino-terminal segment of pro-TGF-cY that 
precedes the TGF-ol sequence (27, 28, 31). The 20-22-kDa 
form was then chased into a 17-kDa form (Fig. 1, A and B). 
This form still retained the TGF-o( epitopes suggesting that 
the loss of mass was due to the cleavage of the amino-terminal 
segment that precedes the TGF-a sequence. Conversion of 
the 20-22-kDa pro-TGF-a form to the 17-kDa pro-TGF-cu 












FIG. 1. Biosynthesis of TGF-a in CHO-TGF-a cells. CHO- 
TGF-a cells were metabolically labeled with [%]cysteine for 15 min. 
The label was then chased with regular unlabeled medium for the 
indicated time periods. Cell lysates (A, B) and media (C) were 
immunoprecipitated with antibodies against the carboxyl-terminal 
region of pro-TGF-cu (A) or against a TGF-a sequence (B, C). 
Radiolabeled immunoprecipitated products were displayed by gel 
electrophoresis and fluorography of the resulting gels. The various 
products were identified as pro-TGF-a forms, mature TGF-a, or the 
transmembrane plus cytoplasmic domain (C-Tail) of pro-TGF-a, as 
described in the text. The position and molecular mass of protein 
standards are indicated. K, kilodalton. 
form was relatively rapid, being half-maximal after 30 min of 
chase and essentially complete by 60 min. 
Further processing of pro-TGF-cy was slow and led to con- 
version of the 17-kDa form to a 15-kDa product. Conversion 
to this product was not complete until 4 h after synthesis 
(Fig. L4). The 15kDa product was not recognized by anti- 
TGF-(U antibodies suggesting that it consisted of the trans- 
membrane domain plus the cytoplasmic domain of pro-TGF- 
LY left with the cell after release of mature TGF-o(. Appearance 
of mature TGF-a in the medium was only detectable after 
pro-TGF-cY was converted to the 15kDa product (Fig. 1C).3 
3 The appearance of free mature TGF-a in the incubation medium 
reproducibly lagged behind the conversion of pro-TGF-ol to the 15- 
kDa form. The reason for this lag is unknown but might be due to a 
slow diffusion of de nouo cleaved TGF-LU from the cell layer. Cell 
layer-associated TGF-a would be lost during the washes that preceded 
lysis and immunoprecipitation of cellular material. 
FIG. 2. Pro-TGF-a exposed on the surface of CHO-TGF-a 
cells. CHO-TGF-a cells were surface-labeled with ‘*‘I. Cell lysates 
were immunoprecipitated with anti-pro-TGF-a antibodies in the 
absence (-) or presence (+) or excess (5 pM) synthetic peptide against 
which the antibodies had been raised. Immunoprecipitates were sub- 
jected to gel electrophoresis and autoradiography. 18K, the specifi- 
cally immunoprecipitated 18-kDa radiolabeled product. 
The slow rate of cleavage of the 17-kDa pro-TGF-a form 
suggested that if pro-TGF-cu were processed intracellularly it 
would have to be retained inside the cell for a relatively long 
time (up to 4 h). Alternatively, pro-TGF-cu processing might 
take place after this molecule had reached the cell surface. 
Two sets of experiments were performed to investigate 
these possibilities. First, CHO-TGF-LU cells were surface-la- 
beled with 125I to determine if pro-TGF-ol reached the cell 
surface before being cleaved. Immunoprecipitation of lysates 
from these cells yielded an 1%kDa labeled product specifically 
recognized by anti-pro-TGF-cY antibodies (Fig. 2). This prod- 
uct is identified as the iz51-labeled derivative of the 17-kDa 
pro-TGF-a form. Relative to the 17-kDa form, the 20-22-kDa 
pro-TGF-cY form was not detectable, or was detectable only 
after prolonged autoradiographic exposure (see Fig. 5). We 
attribute this to the relatively short life of the 20-22-kDa 
product. 
The second set of experiments was designed to probe the 
susceptibility of pro-TGF-a to cleavage by elastase. Elastase 
preferentially cleaves at alanine-, leucine-, and valine-rich 
sequences (40). Ala-Ala-Ala-/-Val-Val and Leu-Leu-Ala-/- 
Val-Val are the sequences and cleavage sites that flank the 
TGF-(r sequence (9, 10). Elastase effectively cleaves the first 
one of these two sites in the pro-TGF-cu extracellular portion 
that is released as a soluble product by certain transformed 
cells (30). To determine the sensitivity to elastase, CHO- 
TGF-(Y cell cultures that had been radioactively pulsed and 
then metabolically chased for various times were incubated 
with elastase for a short period. This treatment did not cleave 
the nascent 18-kDa pro-TGF-cY form or the fully glycosylated 
20-22-kDa pro-TGF-cY in cells that had been chased for only 
15 min (Fig. 3). This result was expected since pro-TGF-a 
labeled in this short pulse should still be mostly inside the 
cell and protected from exogenous elastase action. Thus, this 
experimental condition served as a negative control to indi- 
cate that elastase action was effectively stopped before prep- 
aration of cell lysates. However, the metabolically labeled 20- 
22-kDa pro-TGF-cy form became accessible to cleavage by 
elastase 30 min after synthesis (Fig. 3). Elastase converted 
most of this form to a 17-kDa product. Interestingly, elastase 
action led to accumulation of this product with no further 
cleavage. The metabolically generated 17-kDa product was 
also resistant to exogenous elastase throughout the course of 
the chase (Fig. 3) suggesting that the action of exogenous 
elastase mimicked the first pro-TGF-a cleavage event but not 
the second one. 
pro-TGF-a Processing in Glysosylation-defective Cell Mu- 
tants-Next, we examined the role of glycolysation on the 
biosynthesis and processing of pro-TGF-a in IdlD-TGF-a 
Cell Surface pro-TGF-cu Processing 6413 
cells. The phenotype of 1dlD cells has been described in detail 
(35). Briefly, 1dlD cells are deficient in UDP-galactose/UDP- 
N-acetylgalactosamine-4-epimerase and, therefore, cannot 
synthesize galactose or N-acetylgalactosamine from glucose. 
Under normal culture conditions with glucose as the only 
sugar substrate, the defect in 1dlD cells leads to formation of 
glycoprotein cores lacking mucin type O-linked glycan chains 
whose synthesis is initiated by linkage of GalNAc to a serine 
or threonine residue. GalNAc added to the medium of 1dlD 
cells is converted to nucleotide sugar by a salvage pathway 
that allows initiation of O-linked glycan chain synthesis to 
occur. However, in the absence of added galactose, 1dlD cells 
cannot complete the synthesis of O-linked and certain N- 
linked glycan chains. Addition of both GalNAc and galactose 
is necessary to obtain the normal glycosylation phenotype in 
1dlD cells (35). 
Fig. 4A shows that, in the presence of added GalNAc and 
galactose, IdlD-TGF-a cells exhibited a pro-TGF-a biosyn- 
thetic pattern similar to that of CHO-TGF-a cells. Thus, 
galactose- and GalNAc-supplemented IdlD-TGF-a cells syn- 
thesized pro-TGF-a as an 18-kDa product that was rapidly 
converted to a 20-22-kDa form followed by conversion to a 
17-kDa form and then a 15-kDa product. The kinetics of these 
last two steps were similar (tu = 60 min), which contrasts 
with the different kinetics of these two steps seen in CHO- 
TGF-a cells. A 22-24-kDa labeled product immunoprecipi- 
tated from IdLD-TGF-a cells in these experiments (Fig. 4) was 
nonspecific as determined by its presence in immunoprecipi- 
tates obtained with excess immunogenic synthetic peptide 
(data not shown). 
In the absence of added galactose and GalNAc, IdlD-TGF- 
LY cells synthesized pro-TGF-cu as a l7-kDa product that was 
converted to a 19-kDa form rather than the 20-22-kDa form 
Chase Time (min) 1 15 1 30 ) 45 1 75 135 255 
Elastase - + ( - + - + - + - + I- +m 
-24 
‘O-Z,“5 i#& .* ,. -20 
17K’ **I),*cr,r 4” 15Kr -14 
FIG. 3. Susceptibility of pro-TGF-cr to exogenous elastase. 
CHO-TGF-o cells metabolically labeled with [““Slcysteine for 15 min 
were chased with regular unlabeled medium for the indicated time 
periods. Porcine pancreatic elastase (25 fig/ml) was present during 
the last 15 min of the chase in the indicated (+) samples. Cell lysates 
were immunoprecipitated with anti-pro-TGF-ct antibodies and dis- 
played by electrophoresis and fluorography. 
seen in the wild type CHO cells (Fig. 4C). A 19-kDa form was 
also produced in IdlD-TGF-a cells supplemented with galac- 
tose but not GalNAc. These results suggested that both O- 
linked glycan chains and galactose-independent N-linked gly- 
can chains were added to newly synthesized pro-TGF-a in 
wild type CHO cells, with the O-linked chains being respon- 
sible for most of the electrophoretic shift from 19-kDa to 20- 
22-kDa forms during pro-TGF-cu synthesis. 
The 0-glycosylation defect expressed in IdlD-TGF-a cells 
in the absence of GalNAc did not have a major effect on the 
rate of formation of the 17-kDa pro-TGF-cu form (Fig. 4), its 
accumulation on the cell surface as detected by surface label- 
ing with “‘1 (Fig. 5), or the rate of pro-TGF-cu cleavage and 
appearance of TGF-a in the medium (Fig. 4 and Fig. 6, A-D, 
lanes 1) as compared to IdlD-TGF-0 cells cultured with sugar 
supplements. To determine whether normal O-linked or N- 
linked carbohydrates were required for generation of a bioac- 
tive TGF-a conformation, we tested the ability of TGF-a to 
bind to EGF receptors. TGF-LU produced by IdlD-TGF-a cells 
cultured with or without sugar supplements was incubated 
with EGF receptor-rich A431 cells. TGF-a produced under 
any of these culture conditions was able to bind to EGF 
receptors, and binding was specifically inhibited by the pres- 
ence of an excess EGF (Fig. 6, A-D, lanes 2-5). 
DISCUSSION 
The present studies address several aspects of the process- 
ing of pro-TGF-cw in mammalian cells. Our results indicate 
that generation of soluble TGF-a occurs after pro-TGF-cr 
reaches the cell surface in a process that involves two cleavage 
events that can have markedly different kinetics. 
Evidence to support these conclusions is provided by the 
combined results of metabolic labeling, surface labeling, and 
elastase treatment experiments. The results of metabolic 
labeling experiments in CHO-TGF-LU cells show that newly 
synthesized pro-TGF-or becomes susceptible to cleavage by 
added elastase with kinetics characteristic of the movement 
of a membrane glycoprotein to the cell surface. The results 
also show that the first step of pro-TGF-cu cleavage occurs as 
this molecule becomes exposed on the cell surface or soon 
thereafter. This first step results in trimming of the pro-TGF- 
(Y amino-terminal region. We infer that the initial loss of mass 
is due to trimming of the amino-terminal region because it 
occurs without loss of TGF-a epitopes and is mimicked by 
elastase. Accumulation of pro-TGF-a on the cell surface is 
clearly indicated by the detection of abundant 17-kDa form 
by extracellular radiolabeling. The second step of pro-TGF-cu 
cleavage results in the loss of membrane-bound TGF-a epi- 
topes and the appearance of mature TGF-a in the medium. 
This step occurs with very slow kinetics after pro-TGF-a 
reaches the surface of CHO-TGF-a cells. The results do not 
-24 .24 
20.22Kc -- _ --24 
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FIG. 4. Biosynthesis of TGF-a in IdlD-TGF-a cells. MD-TGF-(U cells were metabolically labeled with [“S] 
cysteine for 15 min. The label was then chased with regular unlabeled medium for the indicated time periods. 
Galactose and GalNAc were present in the media throughout the experiments as indicated. Cell lysates were 
immunoprecipitated with antibodies against the carboxyl-terminal region of pro-TGF-cu. The resulting immuno- 
precipitates were subjected to gel electrophoresis and fluorography to display the labeled pro-TGF-n species. 
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-24 
FIG. 5. Cell surface pro-TGF-a species on the surface of 
IdlD-TGF+ cells. I&D-TGF-cu cells grown in the presence of the 
indicated sugar supplements were surface-labeled with lg51. Cell ly- 
sates were immunoprecipitated with antibodies against the carboxyl- 
terminal region of pro-TGF-a in the absence (-) or presence (+) of 
competing synthetic peptide immunogen. Samples were then sub- 
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FIG. 6. Production of bioactive TGF-a by MD-TGF-a cells 
expressing a protein glycosylation defect. IcUD-TGF-cu cells 
grown in the presence of the indicated sugar supplements were 
metabolically labeled with [%]cysteine for 20 min and chased with 
unlabeled medium for 5 h. The chase medium was collected and 
divided in three aliquots. One aliquot was prepared for immunopre- 
cipitation without any additional treatment (lanes I). The other two 
aliquots were incubated for 3 h at 4 “C with a sparse layer of A431 
cells alone (lanes 2 and 3) or in the presence of 0.75 NM EGF (lanes 
4 and 5). At the end of this incubation, the medium (lanes 2 and 4) 
and the A431 cells (lanes 3 and 5) were prepared for immunoprecip- 
itation. All samples were immunoprecipitated with anti-TGF-n an- 
tibodies, electrophoresed, and subjected to fluorography. Note that 
regardless of the culture conditions, binding of I&D-TGF-(U cell- 
derived TGF-n to A431 cells was quantitative and was completely 
inhibited by the presence of excess EGF. 
exclude the possibility that final cleavage of pro-TGF-cy occurs 
intracellularly by internalization of this molecule from the 
cell surface. 
Soluble TGF-n is generated by cleavage of pro-TGF-cu at 
the carboxyl side of residues Ala”’ and Ala= (3, 9, 10). The 
amino acid sequences around the cleavage sites in rat pro- 
TGF-LU are Ala-Ala-Ala3”-Val-Val and Leu-Leu-AlaM-Val-Val, 
respectively (9, 10). The leucine-, alanine-, and valine-rich 
nature of both sequences predicts that they should be good 
substrates for elastase-like enzymes (40). Indeed, elastase has 
been previously shown to effectively cleave the TGF-cu amino- 
terminal site in the pro-TGF-cu extracellular portion released 
as a soluble product by transformed cells (30). However, the 
present studies suggest that the Ala** site is resistant to 
cleavage by exogenous pancreatic elastase as well as by the 
cellular pro-TGF-cu processing enzyme(s) in CHO-TGF-ol 
cells. Resistance to cleavage at this site leads to accumulation 
of pro-TGF-cu as a ccl1 surface protein. Resistance to cleavage 
might be due to the proximity of this site to the transmem- 
brane sequence that starts at residue 97 following a Lys-Lys 
sequence (9, 10). The possibility that cleavage at Lys-Lysg6 
must occur first to render the AlaM site accessible to cleaving 
enzymes is unlikely because pro-TGF-cu forms mutated at and 
around residue 88 are not cleaved when they are expressed in 
various cell types including the parental CHO cells used here 
(33, 34).4 
Certain cell lines release into the medium a partially proc- 
essed pro-TGF-ol form that consists of the TGF-cu sequence 
extended with the heterogeneously glycosylated amino-ter- 
minal segment of pro-TGF-a (30-32). This segment is 16 or 
38 amino acid residues long depending on whether the signal 
sequence is cleaved or not (9, 1O).5 The existence of this 
soluble form indicates that in some cell types cleavage at Alas8 
can occur before cleavage at Ala”*. Production of a soluble 
form larger than TGF-a was observed in MD-TGF-cu cells 
(Fig. 6) but not in CHO-TGF-a cells (Fig. lA). In galactose 
plus GalNAc-supplemented MD-TGF-cu cells, this form mi- 
grates on electrophoresis gels as a lo-kDa product. Production 
of this form by MD-TGF-LU cells but not CHO-TGF-LU cells 
could be explained by the observation that in the former cell 
line the kinetics of cleavage at both TGF-a-flanking sites are 
very similar, allowing TGF-cu to abandon the cell surface 
before their N-terminal extension has been trimmed. These 
observations indicate cell-specific differences in the relative 
ability to cleave pro-TGF-cu at the two TGF-cu flanking sites 
and leave open the possibility that cleavage at each of these 
two sites is mediated by separate enzymes. 
The role of N-glycosylation in the biosynthesis of pro-TGF- 
cy has been determined using the inhibitor of co-translational 
N-linked glycan chain addition, tunicamycin. Tunicamycin 
interferes with the processing of pro-TGF-cu in retrovirally 
transformed rat embryo fibroblasts (31) but not in transfected 
CHO cells (27), suggesting that tunicamycin action interferes 
with certain cell-specific pro-TGF-cy processing activities. No 
specific inhibitors of protein 0-glycosylation have been avail- 
able to date to probe the role of this modification in the 
biosynthesis and activity of glycoproteins. However, the mu- 
tant CHO 1dlD cell line provides an ideal system to determine 
the role of 0-glycosylation because depending on the culture 
conditions these cells either display their inability to initiate 
biosynthesis of O-linked mucin-type glycan chains or they 
bypass this defect (35). Our results show that the rate of 
biosynthesis and cleavage of pro-TGF-cu, and the production 
of a bioactive TGF-o( conformation are not markedly altered 
in 1dlD cells expressing the defect in 0-glycosylation. Two 
other glycoproteins, human chorionic gonadotropin and apo- 
lipoprotein E, have been described whose rate of synthesis in 
1dlD cells is not affected by lack of 0-glycosylation (41, 42). 
However, both these glycoproteins are soluble secretory prod- 
ucts, not membrane components. The present results contrast 
with the requirement of 0-glycosylation for normal biosyn- 
thesis of the other four different membrane glycoproteins 
examined to date. Krieger and co-workers (35,42) have found 
that expression of low density lipoprotein receptor, decay 
4 J. Teixido, D. C. Lee, and J. Massague, unpublished work. 
,’ Evidence suggests that the pro-TGF-cu signal sequence is cleaved 
in CHO cells (34) but not in other cell lines (31) or in pro-TGF-cu 
translated in vitro in the presence of dog pancreas microsomes (28). 
These apparent differences in processing may result from cell-specific 
differences in glycosylation of sites found near the signal peptide 
cleavage site (9, 10). 
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accelerating factor, and Epstein-Barr virus major antigen 
glycoprotein in ldZD cells leads to rapid degradation of these 
membrane glycoproteins when they reach the cell surface 
after synthesis, whereas the non-O-glycosylated interleukin- 
2 receptor is missorted or retained intracellularly never reach- 
ing the surface of 1dlD cells (43). Thus, pro-TGF-a represents 
an exception among cell surface glycoproteins examined to 
date in that its sorting, expression, and processing do not 
seem to be affected by 0-glycosylation. 
We speculate that the stepwise nature of pro-TGF-a proc- 
essing might be the object of regulatory mechanisms that 
would control the rate of conversion of this molecule from a 
membrane component to a diffusible autocrine/paracrine fac- 
tor. It will be of interest to identify the enzymes involved in 
this conversion and the factors that may regulate their activ- 
ity. 
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